GlobalRPh Renal Dosing Masterv7.4
Renal Dosing Master: fast drug lookup
Source review / handoff

Aprepitant (Aponvie), IV emulsion

One or two intact local summaries. No averaged regimen, patient-specific dose or automatic source preference.

Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.

Share or print this source review

1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.

Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.

Clinical context remains essential

Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.

Check source scope before reading a dose

Aponvie - labeled renal guidance

Product / population
Aprepitant (Aponvie), IV emulsion
Renal method
Renal impairment categories as defined by the cited product label
Source revision
DailyMed SPL version 8, posted Apr 09, 2026
Retrieved
2026-11-07
Local review status
Selected renal passages reviewed; independent clinician adjudication pending.

Documented differences and cautions on this drug

All record notes are retained here, including notes about sources not selected in this review.

Aponvie - product and source limitations

This finding concerns the single-dose IV emulsion regimen.

What to reconcile: Apply only to the stated formulation, indication and renal population.

Selected renal passages reviewed; independent clinician adjudication pending.

Open this note and its source references
Official

Aponvie - labeled renal guidance

Open original reference

DailyMed / product prescribing information · Aprepitant (Aponvie), IV emulsion

Renal method: Renal impairment categories as defined by the cited product label
Source date: DailyMed SPL version 8, posted Apr 09, 2026
Retrieved: 2026-11-07

Pharmacokinetic observation only. A drug-exposure observation is not itself a dose recommendation.

Selected renal passages reviewed; independent clinician adjudication pending.

Renal guidance: Prescribing information, renal precautions and clinical pharmacology

Renal impairment is not expected to meaningfully affect exposure after a single 32 mg IV dose of aprepitant for postoperative nausea and vomiting prevention. This finding concerns the single-dose IV emulsion regimen.

RDM74-aponvie-official-1 · Source locator: Renal guidance: Prescribing information, renal precautions and clinical pharmacology

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d1b111eb-659a-496b-a86a-8f0fa370f147
Retrieved
2026-11-07
Renal-function method
Renal impairment categories as defined by the cited product label
Source date/version
DailyMed SPL version 8, posted Apr 09, 2026
Hash meaning
SHA-256 of the local selected-source summary
Local summary SHA-256
93e4c55798e0ee4e8da71f0d5f12855b14cd36f30c6cbff494132994a3124136

Document the clinical decision separately

This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.

GlobalRPh Renal Dosing Master v7.4. Review the retrieval and revision dates attached to each source. Selecting a reference does not imply clinical verification.

Pinned reference: https://globalrph.com/blogCalcs/renal-dosing-master/compare.php?id=rx-aponvie&s1=RDM74-aponvie-official&h1=dcce4081b23e847bf897dc44a8de90b44884ac1ab6d54c232f0981c1bcd0fffc

Top